Xenon Pharmaceuticals pauses enrollment for azetukalner trials
Xenon Pharmaceuticals said it is voluntarily pausing trial enrollment for azetukalner for depression and bipolar treatment after adverse events, pending consultation.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.